Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,837

Sector

Biotechnology & Medical Research

Calendar

08-31 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-18	387.00 $	+0.68%	625,618
25-07-17	384.40 $	+8.16%	1,191,300
25-07-16	355.40 $	-0.62%	483,525
25-07-15	357.60 $	+4.32%	1,156,254
25-07-14	342.80 $	+0.82%	594,557

Delayed Quote Hong Kong S.E., July 18, 2025 at 03:17 am

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

384.40HKD

Average target price

330.26HKD

Spread / Average Target

-14.08%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Hong Kong S.E. Other stock markets 03:17:14 2025-07-18 EDT			5-day change	1st Jan Change
387.00 ^HKD	+0.68%		+13.82%	+136.99%

06-12	SKB Biopharma Raises HK$1.94 Billion from Share Placement	MT
06-12	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	CI

Capitalization	80.36B 87.85B 11.19B 9.66B 9.01B 8.35B 15.39B 963B 17.27B 109B 41.11B 451B 41.99B 41.12B 1,662B	P/E ratio 2025 *	-129x	P/E ratio 2026 *	-935x
Enterprise value	78.97B 86.33B 11B 9.49B 8.85B 8.2B 15.12B 946B 16.97B 107B 40.4B 443B 41.26B 40.41B 1,634B	EV / Sales 2025 *	40x	EV / Sales 2026 *	25.8x
Free-Float	59.59%	Yield 2025 *	-	Yield 2026 *	-

SKB Biopharma Raises HK$1.94 Billion from Share Placement	06-12	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives A Clinical Trial Notice Approving the Investigational New Drug Application for the Its CLDN18.2-Directed Antibody-Drug Conjugate SKB315 in Combination of the Anti-Programmed Death Ligand 1 (PD-L1) Monoclonal Antibody Tagitanlimab	06-12	CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination with Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer	06-11	CI
Sichuan Kelun-Biotech Lung Cancer Combo Gets Breakthrough Tag in China; Shares Slide 3%	06-11	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results from Phase 1/2 Study of Kelun-Biotech's Trop2 Adc Sacituzumab Tirumotecan	06-10	CI
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC	06-07	CI
SKB Biopharmaceutical Seeks to Raise HK$1.94 Billion from Share Placement; Shares Fall 7%	06-05	MT
Sichuan Kelun-Biotech Biopharmaceutical Placing 5.9 Mln Placing H Shares At HK$331.8 Per Placing H Share	06-04	RE
Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet Shows	06-04	RE
Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. to Present Results from Six Clinical Studies	05-23	CI
SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract	05-23	MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives an Upfront Payment from Windward Bio AG	05-23	CI
Chinese Regulator Accepts SKB Biopharma's New Indication Application for Breast Cancer Drug	05-22	MT

Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$300 from HK$240, Keeps at Buy	03-26	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy	02-18	MT
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$195.51 From HK$196.40, Keeps at Buy	24-08-20	MT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Valuation: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Chart: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Latest news: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Analysts' recommendations: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Press Releases: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024	03-26	PR
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).	01-11	PR

1 day	+0.68%
1 week	+13.82%
Current month	+18.28%
1 month	+12.96%
3 months	+29.00%
6 months	+130.77%
Current year	+136.99%

1 week	329.8	397
1 month	314.2	397
Current year	153.9	397
1 year	142	397
3 years	60.6	397
5 years	60.6	397
10 years	60.6	397

Manager	Title	Age	Since
Jun You Ge CEO	Chief Executive Officer	53	2022-02-28
Ze Jian Zhou DFI	Director of Finance/CFO	42	2022-08-16
Xiao Ping Jin CTO	Chief Tech/Sci/R&D Officer	48	2021-09-05

Director	Title	Age	Since
Ge Xin Liu CHM	Chairman	74	2022-02-28
Jun You Ge BRD	Director/Board Member	53	2022-02-24
Si Chuan Liu BRD	Director/Board Member	41	2016-11-21

	2025 *	2026 *
Net sales	1.97B 2.16B 275M 237M 221M 205M 378M 23.65B 424M 2.68B 1.01B 11.07B 1.03B 1.01B 40.83B	3.06B 3.34B 426M 368M 343M 318M 586M 36.67B 657M 4.16B 1.57B 17.17B 1.6B 1.57B 63.29B
Net income	-612M -669M -85.27M -73.58M -68.62M -63.58M -117M -7.34B -132M -832M -313M -3.44B -320M -313M -12.66B	-76.5M -83.63M -10.66M -9.19M -8.58M -7.95M -14.65M -917M -16.44M -104M -39.14M -429M -39.97M -39.14M -1.58B
Net Debt	-1.39B -1.52B -194M -167M -156M -145M -266M -16.68B -299M -1.89B -712M -7.81B -727M -712M -28.79B	-1.5B -1.64B -208M -180M -168M -155M -286M -17.92B -321M -2.03B -765M -8.39B -781M -765M -30.94B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.68%	+13.82%	+158.00%	-	11.19B
ARGENX SE	-0.02%	+2.12%	+15.27%	+34.73%	34.81B
WUXI APPTEC CO., LTD.	+2.80%	+15.51%	+106.58%	-22.84%	32.25B
BIONTECH SE	-1.29%	-2.53%	+28.41%	-31.22%	27.34B
SUMMIT THERAPEUTICS INC.	-2.26%	+6.76%	+196.78%	+2,411.82%	20.52B
INSMED INCORPORATED	-0.40%	+7.77%	+37.90%	+350.37%	19.79B
AKESO, INC.	+0.29%	+23.59%	+247.58%	+512.25%	15.95B
WUXI BIOLOGICS (CAYMAN) INC.	+0.71%	+7.13%	+154.00%	-62.61%	14.67B
GENMAB A/S	+1.00%	+3.77%	-22.77%	-43.66%	13.57B
EXELIXIS, INC.	+0.13%	-0.66%	+99.33%	+110.26%	12.24B
Average	+0.19%	+7.27%	+102.11%	+362.12%	20.23B
Weighted average by Cap.	+0.20%	+5.99%	+91.03%	+335.09%